MHH Logo

"Cardiovascular Phenotyping and Translational Strategies"


·         Cardiovascular disease is the number-one health problem worldwide.

·         Development of therapeutic approaches depends on suitable small and large animal models that replicate pathogenesis in humans.

·         Non-coding RNAs are novel therapeutic targets as master regulators of gene expression by controlling many physiologic and pathologic processes.

·         Our primary focus is to develop synthetic antisense oligonucleotide based therapeutics targeting specific non-coding RNAs as a revolutionary pharmacological tool fighting cardiovascular diseases.



·         1. Project Cardior

Preclinical development of a new miRNA inhibitor therapeutics in heart failure


·         2. Non-coding RNA based therapy of heart failure

We aim to develop and test microRNA based therapies in small and large animal models of myocardial infarction and congestive heart failure.


·         2. Antisense oligo pharmacology

Pharmacological characterization of synthetic non-coding RNA inhibitors



·         Dr. med. Sandor Batkai, PhD, Group Leader (see CV)

·         Ariana Foinquinos, PhD-student

·         Markus Herkt, PhD-student